ImmunoPrecise Antibodies Ltd. Share Price Toronto S.E.
Equities
IPA
CA45257F2008
Pharmaceuticals
Sales 2024 * | 24.59M 17.87M 1.43B | Sales 2025 * | 29.82M 21.67M 1.74B | Capitalization | 46.14M 33.54M 2.69B |
---|---|---|---|---|---|
Net income 2024 * | -12M -8.72M -699M | Net income 2025 * | -9M -6.54M -525M | EV / Sales 2024 * | 1.88 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.55 x |
P/E ratio 2024 * |
-3.65
x | P/E ratio 2025 * |
-4.94
x | Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.41% |
Latest transcript on ImmunoPrecise Antibodies Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 20/02/18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 28/09/23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 04/09/23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 20/02/18 |
1st Jan change | Capi. | |
---|---|---|
-2.35% | 89.33B | |
+3.29% | 41.19B | |
-15.40% | 31.87B | |
+52.47% | 24.52B | |
-14.35% | 15.68B | |
-39.65% | 12.23B | |
-6.52% | 12.34B | |
-13.41% | 12.21B | |
+5.32% | 8.83B |